Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - SUPERNUS PHARMACEUTICALS, INC. | a16-22709_1ex32d2.htm |
| EX-32.1 - EX-32.1 - SUPERNUS PHARMACEUTICALS, INC. | a16-22709_1ex32d1.htm |
| EX-31.2 - EX-31.2 - SUPERNUS PHARMACEUTICALS, INC. | a16-22709_1ex31d2.htm |
| EX-31.1 - EX-31.1 - SUPERNUS PHARMACEUTICALS, INC. | a16-22709_1ex31d1.htm |
| EX-23.1 - EX-23.1 - SUPERNUS PHARMACEUTICALS, INC. | a16-22709_1ex23d1.htm |
| 10-K/A - 10-K/A - SUPERNUS PHARMACEUTICALS, INC. | a16-22709_110ka.htm |
EXHIBIT 23.2
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
The Board of Directors
Supernus Pharmaceuticals, Inc.:
We consent to the incorporation by reference in the registration statements (Nos. 333-181479, 333-201049) on Form S-8, and (No. 333-200716) on Form S-3 of Supernus Pharmaceuticals, Inc. of our report dated March 8, 2016, except as to Note 2, which is as of January 20, 2017 with respect to the consolidated balance sheet of Supernus Pharmaceuticals, Inc. and subsidiary as of December 31, 2015, and the related consolidated statements of operations, comprehensive income (loss), changes in stockholders’ equity, and cash flows for the year then ended, which report appears in the December 31, 2015 Annual Report on Form 10-K/A of Supernus Pharmaceuticals, Inc..
|
|
/s/ KPMG LLP |
|
|
|
|
Baltimore, Maryland |
|
|
January 20, 2017 |
|